ACADIA PHARMACEUTICALS INC (ACAD) Stock Fundamental Analysis
USA - NASDAQ:ACAD - US0042251084 - Common Stock
23.61 USD
-0.59 (-2.44%)
23.61 USD
0 (0%)
Taking everything into account, ACAD scores 6 out of 10 in our fundamental rating. ACAD was compared to 540 industry peers in the Biotechnology industry. While ACAD has a great health rating, its profitability is only average at the moment. ACAD is not priced too expensively while it is growing strongly. Keep and eye on this one! With these ratings, ACAD could be worth investigating further for growth investing!.
1. Profitability
1.1 Basic Checks
In the past year ACAD was profitable.
ACAD had a positive operating cash flow in the past year.
In the past 5 years ACAD reported 4 times negative net income.
The reported operating cash flow has been mixed in the past 5 years: ACAD reported negative operating cash flow in multiple years.
1.2 Ratios
ACAD has a Return On Assets of 18.13%. This is amongst the best in the industry. ACAD outperforms 96.48% of its industry peers.
Looking at the Return On Equity, with a value of 27.01%, ACAD belongs to the top of the industry, outperforming 97.04% of the companies in the same industry.
ACAD has a better Return On Invested Capital (8.85%) than 93.52% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 18.13% | ||
| ROE | 27.01% | ||
| ROIC | 8.85% |
ROA(3y)-8.62%
ROA(5y)-17.17%
ROE(3y)-12.41%
ROE(5y)-22.64%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
ACAD has a better Profit Margin (21.80%) than 95.00% of its industry peers.
With an excellent Operating Margin value of 8.86%, ACAD belongs to the best of the industry, outperforming 91.67% of the companies in the same industry.
The Gross Margin of ACAD (91.97%) is better than 92.41% of its industry peers.
ACAD's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 8.86% | ||
| PM (TTM) | 21.8% | ||
| GM | 91.97% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.7%
GM growth 5Y-0.59%
2. Health
2.1 Basic Checks
ACAD has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
ACAD has more shares outstanding than it did 1 year ago.
ACAD has more shares outstanding than it did 5 years ago.
There is no outstanding debt for ACAD. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
ACAD has an Altman-Z score of 5.15. This indicates that ACAD is financially healthy and has little risk of bankruptcy at the moment.
ACAD's Altman-Z score of 5.15 is fine compared to the rest of the industry. ACAD outperforms 75.74% of its industry peers.
ACAD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 5.15 |
ROIC/WACC0.92
WACC9.59%
2.3 Liquidity
A Current Ratio of 2.91 indicates that ACAD has no problem at all paying its short term obligations.
ACAD has a worse Current ratio (2.91) than 64.63% of its industry peers.
A Quick Ratio of 2.83 indicates that ACAD has no problem at all paying its short term obligations.
The Quick ratio of ACAD (2.83) is worse than 64.07% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.91 | ||
| Quick Ratio | 2.83 |
3. Growth
3.1 Past
ACAD shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 150.00%, which is quite impressive.
Looking at the last year, ACAD shows a quite strong growth in Revenue. The Revenue has grown by 14.41% in the last year.
Measured over the past years, ACAD shows a very strong growth in Revenue. The Revenue has been growing by 23.08% on average per year.
EPS 1Y (TTM)150%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-20%
Revenue 1Y (TTM)14.41%
Revenue growth 3Y25.54%
Revenue growth 5Y23.08%
Sales Q2Q%9.34%
3.2 Future
ACAD is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 41.29% yearly.
ACAD is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 11.25% yearly.
EPS Next Y19.98%
EPS Next 2Y34.15%
EPS Next 3Y43.65%
EPS Next 5Y41.29%
Revenue Next Year9.96%
Revenue Next 2Y10.97%
Revenue Next 3Y11.46%
Revenue Next 5Y11.25%
3.3 Evolution
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 52.47, which means the current valuation is very expensive for ACAD.
ACAD's Price/Earnings ratio is rather cheap when compared to the industry. ACAD is cheaper than 91.30% of the companies in the same industry.
The average S&P500 Price/Earnings ratio is at 27.30. ACAD is valued rather expensively when compared to this.
With a Price/Forward Earnings ratio of 27.33, ACAD can be considered very expensive at the moment.
Based on the Price/Forward Earnings ratio, ACAD is valued cheaper than 91.30% of the companies in the same industry.
ACAD's Price/Forward Earnings ratio indicates a valuation a bit more expensive than the S&P500 average which is at 22.73.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 52.47 | ||
| Fwd PE | 27.33 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, ACAD is valued cheaper than 92.59% of the companies in the same industry.
92.96% of the companies in the same industry are more expensive than ACAD, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 45.09 | ||
| EV/EBITDA | 26.09 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates ACAD does not grow enough to justify the current Price/Earnings ratio.
ACAD has a very decent profitability rating, which may justify a higher PE ratio.
A more expensive valuation may be justified as ACAD's earnings are expected to grow with 43.65% in the coming years.
PEG (NY)2.63
PEG (5Y)N/A
EPS Next 2Y34.15%
EPS Next 3Y43.65%
5. Dividend
5.1 Amount
ACAD does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
23.61
-0.59 (-2.44%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners103.86%
Inst Owner Change-2.36%
Ins Owners0.31%
Ins Owner Change2.18%
Market Cap3.98B
Analysts76.15
Price Target30.71 (30.07%)
Short Float %5.95%
Short Ratio5.1
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)5.63%
Min EPS beat(2)-3.19%
Max EPS beat(2)14.46%
EPS beat(4)2
Avg EPS beat(4)-13.96%
Min EPS beat(4)-109.07%
Max EPS beat(4)41.97%
EPS beat(8)5
Avg EPS beat(8)7.72%
EPS beat(12)7
Avg EPS beat(12)13.12%
EPS beat(16)10
Avg EPS beat(16)17.21%
Revenue beat(2)1
Avg Revenue beat(2)-0.42%
Min Revenue beat(2)-0.93%
Max Revenue beat(2)0.08%
Revenue beat(4)1
Avg Revenue beat(4)-2.63%
Min Revenue beat(4)-8.33%
Max Revenue beat(4)0.08%
Revenue beat(8)4
Avg Revenue beat(8)-0.28%
Revenue beat(12)5
Avg Revenue beat(12)-0.9%
Revenue beat(16)7
Avg Revenue beat(16)-1.31%
PT rev (1m)5.24%
PT rev (3m)12.68%
EPS NQ rev (1m)6.66%
EPS NQ rev (3m)7.84%
EPS NY rev (1m)7.65%
EPS NY rev (3m)-3.06%
Revenue NQ rev (1m)0.07%
Revenue NQ rev (3m)0.76%
Revenue NY rev (1m)0.65%
Revenue NY rev (3m)0.55%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 52.47 | ||
| Fwd PE | 27.33 | ||
| P/S | 3.91 | ||
| P/FCF | 45.09 | ||
| P/OCF | 21.19 | ||
| P/B | 4.84 | ||
| P/tB | 5.63 | ||
| EV/EBITDA | 26.09 |
EPS(TTM)0.45
EY1.91%
EPS(NY)0.86
Fwd EY3.66%
FCF(TTM)0.52
FCFY2.22%
OCF(TTM)1.11
OCFY4.72%
SpS6.04
BVpS4.87
TBVpS4.2
PEG (NY)2.63
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 18.13% | ||
| ROE | 27.01% | ||
| ROCE | 10.08% | ||
| ROIC | 8.85% | ||
| ROICexc | 59.33% | ||
| ROICexgc | 412.73% | ||
| OM | 8.86% | ||
| PM (TTM) | 21.8% | ||
| GM | 91.97% | ||
| FCFM | 8.67% |
ROA(3y)-8.62%
ROA(5y)-17.17%
ROE(3y)-12.41%
ROE(5y)-22.64%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.7%
GM growth 5Y-0.59%
F-Score6
Asset Turnover0.83
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 729.13% | ||
| Cap/Sales | 9.78% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 180.83% | ||
| Profit Quality | 39.76% | ||
| Current Ratio | 2.91 | ||
| Quick Ratio | 2.83 | ||
| Altman-Z | 5.15 |
F-Score6
WACC9.59%
ROIC/WACC0.92
Cap/Depr(3y)241.55%
Cap/Depr(5y)203.25%
Cap/Sales(3y)1.86%
Cap/Sales(5y)1.5%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)150%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-20%
EPS Next Y19.98%
EPS Next 2Y34.15%
EPS Next 3Y43.65%
EPS Next 5Y41.29%
Revenue 1Y (TTM)14.41%
Revenue growth 3Y25.54%
Revenue growth 5Y23.08%
Sales Q2Q%9.34%
Revenue Next Year9.96%
Revenue Next 2Y10.97%
Revenue Next 3Y11.46%
Revenue Next 5Y11.25%
EBIT growth 1Y307.77%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-22.34%
EBIT Next 3Y29.08%
EBIT Next 5Y49.91%
FCF growth 1Y218.86%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y647.78%
OCF growth 3YN/A
OCF growth 5YN/A